Breast Cancer
Conditions
Keywords
Breast Cancer, AZD4547, Safety Run-In, FGFR1, ER positive breast cancer, Single arm phase IIa study
Brief summary
This study is looking at a new drug called AZD4547 which is being tested for the treatment of oestrogen receptor positive breast cancer. AZD4547 is a drug which specifically blocks proteins called fibroblast growth factor receptors (FGFR1) that are involved in the processes that help cancer cells to grow. These proteins may also be responsible for the development of resistance to hormonal therapies used to treat some breast cancers. AZD4547 is not yet approved for use in breast cancer and is therefore being used in this study as a research drug. The investigators will also test the theory that it is not necessary for high levels of FGFR1 to be present in the body to see benefit from AZD4547. (Stage 1 only)
Detailed description
The study will be carried out in two stages. Stage 1 is to find a suitable dose of AZD4547 which can be used together with a class of drugs called nonsteroidal aromatase inhibitors (e.g. anastrozole or letrozole) i.e. a dose which does not cause too many unacceptable side effects. Patients with hormone sensitive (oestrogen receptor positive) breast cancer, whose current treatment with anastrozole or letrozole has recently stopped working properly will be eligible for this stage. Stage 2 will then assess the efficacy of AZD4547, based on the change in tumour size at 12 weeks (or progression if prior to week 12), when used in combination with either anastrozole or letrozole in patients with hormone sensitive (oestrogen receptor positive) breast cancer, who have progressed on treatment with either anastrozole or letrozole in any setting. In both stages, the study will look at how well the new treatment is tolerated. Each patient is only allowed to take part in either stage 1 or 2. The study will be run in 9 Hospitals across England and Scotland.
Interventions
DRUGAZD4547 / anastrozole or letrozole
Patients will continue or restart the NSAI which they have progressed\* on: either anastrozole (1mg) or letrozole (2.5mg), orally, once daily but together with twice daily AZD4547 (80mg). AZD4547 will be given on an intermittent schedule of one week on / one week off. \*Prior to study entry, patients must have taken anastrozole or letrozole at some stage in their treatment to date for breast cancer; and shown evidence of resistance to this therapy. The NSAI does not have to be the most recent line of treatment.
Sponsors
Cancer Research UK
AstraZeneca
Imperial College London
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
FEMALE
Age
25 Years to No maximum
Healthy volunteers
No
Inclusion criteria
Patients must fulfil all of the following criteria. 1. Written (signed and dated) informed consent and be capable of co-operating with treatment and follow-up 2. Aged ≥ 25 years of age (N.B. in line with other studies with AZD4574 and due to concerns of possible effects on the immature skeleton) 3. Post menopausal women. Women will be considered postmenopausal if they have had a bilateral oophorectomy or the following specific requirements apply: Safety run-in: * Women under 50 years old would be considered post-menopausal if they have been amenorrhoeic for 24 months and have follicle-stimulating hormone (FSH) and oestradiol levels in the post-menopausal range. Patients with prior exposure to depot Luteininzing hormone releasing hormones (LHRH) analogues must be 24 months or more following the last administration * Women aged 50 years and older would be considered post-menopausal if they have been amenorrhoeic for 12 months and patients with prior exposure to depot LHRH analogues must be 12 months or more following the last administration * Women rendered amenorrhoeic by adjuvant chemotherapy, who were premenopausal or perimenopausal prior to chemotherapy, must have been amenorrhoeic for at least 24 months Phase IIa: * Women under 50 years old would be considered post-menopausal if they have been amenorrhoeic for 24 months and have follicle-stimulating hormone (FSH) and oestradiol levels in the post-menopausal range. * Women aged 50 years and older would be considered post-menopausal if they have been amenorrhoeic for 12 months * Women rendered amenorrhoeic by adjuvant chemotherapy, who were premenopausal or perimenopausal prior to chemotherapy, must have been amenorrhoeic for at least 24 months * Perimenopausal women rendered amenorrhoeic from exposure to depot LHRH analogues\* * Patients must have taken LHRH analogues for at least 6 months 4. Eastern Cooperative Oncology Group (ECOG) performance status 0-1 with no deterioration over the previous 2 weeks and minimum life expectancy of 12 weeks 5. Histological confirmation of breast cancer with documented positive oestrogen receptor status (ER+) of primary or metastatic tumour tissue according to local laboratory parameters 6. Phase IIa: Mandatory provision of tumour biopsy for assessment of oncology biomarkers 7. Fulfils criteria for previous treatment of breast cancer\*: Safety run-in: * Relapse during a single regimen of adjuvant endocrine therapy with either anastrozole or letrozole or * Progression during first line endocrine therapy with a non-steroidal Aromatase Inhibitor (AI) for advanced breast cancer\*\*. Co-administration of a targeted agent with the non-steroidal AI is permitted providing all toxicities have recovered to CTCAE Grade 1 or below 1 prior regimen of chemotherapy in the advanced setting is permitted. Chemotherapy administered in the adjuvant setting is permitted Phase IIa: o Progressing or progression at some point during breast cancer treatment on endocrine therapy with a non-steroidal AI.\*\*\* Co-administration of a targeted agent with the non-steroidal AI is permitted providing all toxicities have recovered to CTCAE Grade 1 or below. * Prior chemotherapy in the advanced and adjuvant setting is permitted. * Prior treatment with exemestane with or without everolimus is permitted. * Human Epidermal Growth Factor Receptor 2 (HER2) positive breast cancer patients should have been offered at least one prior line of HER2 directed therapy \*\*Advanced breast cancer: metastatic disease or locally advanced disease which is not amenable to treatment with curative intent \*\*\*anastrozole or letrozole does not have to be the most recent therapy 8. Safety run-in: At least one lesion (measurable and/or non-measurable) that can be accurately assessed by CT/MRI/plain x-ray at baseline and follow up visits Phase IIa: At least one lesion ≥ 10mm in the longest diameter at baseline (or ≥ 15mm in the short axis for nodal disease) that can be accurately measured with CT/MRI at baseline and is suitable for accurate repeated measurements. Patients with bone only metastatic cancer must have a lytic or mixed lytic-blastic lesion that can be accurately assessed by CT or MRI. 9. Safety run-in: Study entry must be preceded by a minimum of 21 days of anastrozole or letrozole treatment Phase IIa: No set duration of anastrozole or letrozole treatment prior to study entry.
Exclusion criteria
1. Treatment with any of the following: 1. Safety run-in: more than 1 regimen of endocrine therapy for advanced breast cancer 2. previous exposure to any FGFR inhibitor 3. Safety run in: more than 1 prior regimen of chemotherapy for advanced breast cancer. 4. potent inhibitors or inducers of CYP3A4 or CYP2D6, or substrates of CYP3A4 within 2 weeks prior to first dose of study treatment (3 weeks for St John's Wort) 5. major surgery within 4 weeks prior to first dose of study treatment 6. radiotherapy with a wide field of radiation within 4 weeks prior to first dose of study treatment; or radiotherapy with a limited field of radiation for palliation within 2 weeks before the first dose of study treatment 2. With the exception of alopecia, any unresolved toxicities from prior therapy greater than CTCAE grade 1 at time of starting study 3. Spinal cord compression or brain metastases unless asymptomatic, treated and stable and not requiring steroids for at least 4 weeks prior to start of study treatment 4. Any evidence of severe or uncontrolled systemic diseases or active infection 5. Any of the following cardiac criteria: 1. Resting corrected QT interval (QTc) \>470 ms 2. Any clinically important abnormalities in rhythm, conduction or morphology of resting ECG e.g. complete left bundle branch block, third degree heart block 3. Any factors that increase the risk of QTc prolongation or risk of arrhythmic events such as heart failure, hypokalaemia, congenital long QT syndrome, family history of long QT syndrome or unexplained sudden death under 40 years of age or any concomitant medication known to prolong the QT interval 6. Inadequate bone marrow reserve or organ function as defined by any one of the following parameters: Haemoglobin \< 9.0 g/dL (\<90.0 g/L) Absolute neutrophil count (ANC) \< 1.5 x 109 /L Platelet count \< 100 x 109 /L Alanine aminotransferase \> 2.5 x Upper Limit of Normal (ULN) if no demonstrable liver metastases or \> 5 x ULN in the presence of liver metastases Aspartate aminotransferase \> 2.5 x ULN if no demonstrable liver metastases or \> 5 x ULN in the presence of liver metastases Total bilirubin \> 1.5 x ULN if no demonstrable liver metastases or \> 3 x ULN in the presence of liver metastases Creatinine \> 1.5 times ULN or creatinine clearance \<50ml/min Corrected calcium \> ULN Phosphate \> ULN 7. Refractory nausea and vomiting, chronic gastrointestinal diseases, inability to swallow the formulated Investigational Medicinal Product (IMP) or previous significant bowel resection that would preclude absorption of AZD4547 or anastrozole or letrozole 8. History of hypersensitivity to anastrozole or letrozole 9. History of another malignancy within 5 yrs prior to starting study treatment, except adequately treated basal or squamous cell carcinoma of the skin, carcinoma of the cervix and the disease under study 10. Any of the following ophthalmological criteria:\* * Current evidence or previous history of retinal pigmented epithelium detachment (RPED) * Previous laser treatment or intra-ocular injection for treatment of macular degeneration * Current evidence or previous history of soft drusen, drusenoid RPE detachment and wet macular degeneration. * Current evidence or previous history of retinal vein occlusion (RVO) * Current evidence or previous history of retinal degenerative diseases (e.g. hereditary) \*Patients with uncontrolled glaucoma or intra-ocular pressure \>21 mmHg at screening should be referred for ophthalmological management and the condition controlled prior to first dose of study treatment. 11. Concurrent treatment with another investigational agent or use of another investigational agent within 30 days or 5 half lives, whichever is longer, preceding the first dose of study treatment 12. Concurrent treatment with prohibited medications and wash out period for that drug will not have been completed before starting study medication
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Number of Participants With Serious Adverse Events (SAEs) | Dose limiting toxicity (DLT) assessment window - days 1 to 28 of cycle 1 | Safety and tolerability of AZD4547 to be used in combination with a standard dose of anastrozole or letrozole, as assessed by Dose limiting toxicity (DLT) This is the primary outcome measure in the Safety Run-In part of the study. |
| Proportion of Tumour Size Change at 12 Weeks (or Progression if Prior to Week 12) | 12 weeks | This is the primary outcome measure in the Randomised Phase IIa part of the study. This is the proportion of tumour size change from baseline to week 12 (or progression if prior to week 12) based on local review of results. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Proportion of Tumour Size Change at 6, 20 and 28 Weeks | 6, 20 and 28 weeks | Proportion of tumour size change at 6, 20 and 28 weeks to assess the efficacy of AZD4547 in combination with anastrozole or letrozole. This outcome measure is based on local review. |
| Tumour Response (RECIST Criteria) at 6, 12, 20 and 28 Weeks | 6, 12, 20 and 28 weeks | Tumour response (RECIST criteria) at 6, 12, 20 and 28 weeks to assess the efficacy of AZD4547 in combination with anastrozole or letrozole. This outcome measure is based on local review. |
| Objective Response at 6, 12, 20 and 28 Weeks | 6, 12, 20 and 28 weeks | Objective Response at 6, 12, 20 and 28 weeks to assess the efficacy of AZD4547 in combination with anastrozole or letrozole. The Objective Response Rate (ORR) is defined as the proportion of overall complete response (CR) and overall partial response (PR) among all patients who receive at least one dose of study treatment. This outcome measure is based on local review. |
| Progression Free Survival | 42 months | Progression Free Survival (PFS) was defined as the time from study enrolment to first evidence of progression. Progression is defined as overall progressive disease identified at follow-up or confirmed disease progression at the end of the trial or death. |
Countries
United Kingdom
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| AZD4547 Participants received NSAI (anastrozole (1mg) or letrozole (2.5mg)), orally, once daily together with twice daily AZD4547 (80mg).
AZD4547 will be given on an intermittent schedule of one week on / one week off. | 52 |
| Total | 52 |
Withdrawals & dropouts
| Period | Reason | FG000 |
|---|---|---|
| Overall Study | Adverse Event | 7 |
| Overall Study | Withdrawal by Subject | 1 |
Baseline characteristics
| Characteristic | AZD4547 |
|---|---|
| Age, Categorical <=18 years | 0 Participants |
| Age, Categorical >=65 years | 11 Participants |
| Age, Categorical Between 18 and 65 years | 41 Participants |
| Age, Continuous | 56.5 years |
| Eastern Cooperative Oncology Group (ECOG) Status Fully active | 33 Participants |
| Eastern Cooperative Oncology Group (ECOG) Status Restricted in physically strenuous activity | 19 Participants |
| ECG Abnormal | 19 Participants |
| ECG Normal | 33 Participants |
| Echocardiogram (ECHO) / Multiplegated acquisition (MUGA) Scan Abnormal | 3 Participants |
| Echocardiogram (ECHO) / Multiplegated acquisition (MUGA) Scan Normal | 49 Participants |
| Race/Ethnicity, Customized Ethnicity Black | 2 Participants |
| Race/Ethnicity, Customized Ethnicity Unknown or Not reported | 1 Participants |
| Race/Ethnicity, Customized Ethnicity White | 49 Participants |
| Region of Enrollment United Kingdom | 52 participants |
| Sex: Female, Male Female | 52 Participants |
| Sex: Female, Male Male | 0 Participants |
| Smoking Current | 3 Participants |
| Smoking Never | 29 Participants |
| Smoking Past | 18 Participants |
| Smoking Unknown or not reported | 2 Participants |
| Tumour Grade Grade 1 or 2 | 25 Participants |
| Tumour Grade Grade 3 or 4 | 14 Participants |
| Tumour Grade Unknown | 13 Participants |
Adverse events
| Event type | EG000 affected / at risk |
|---|---|
| deaths Total, all-cause mortality | 2 / 52 |
| other Total, other adverse events | 52 / 52 |
| serious Total, serious adverse events | 10 / 52 |
Outcome results
Primary
Number of Participants With Serious Adverse Events (SAEs)
Safety and tolerability of AZD4547 to be used in combination with a standard dose of anastrozole or letrozole, as assessed by Dose limiting toxicity (DLT) This is the primary outcome measure in the Safety Run-In part of the study.
Time frame: Dose limiting toxicity (DLT) assessment window - days 1 to 28 of cycle 1
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| AZD4547 | Number of Participants With Serious Adverse Events (SAEs) | 10 Participants |
Primary
Proportion of Tumour Size Change at 12 Weeks (or Progression if Prior to Week 12)
This is the primary outcome measure in the Randomised Phase IIa part of the study. This is the proportion of tumour size change from baseline to week 12 (or progression if prior to week 12) based on local review of results.
Time frame: 12 weeks
Population: Out of 52 enrolled patients, 43 patients have analyzable data. Prior to week 12, there were 8 patients who discontinued study treatment prior to progression and 1 patient who had disease progression died before tumour measurements could be taken. Therefore a total of 9 patients cannot be included in the analysis of the primary outcome.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| AZD4547 | Proportion of Tumour Size Change at 12 Weeks (or Progression if Prior to Week 12) | 0.08 Proportion of tumour size change | Standard Deviation 0.32 |
Comparison: Proportion of change in tumour size at 12 weeks (or progression if prior to week 12), when used in combination with either anastrozole or letrozole in ER positive breast cancer patients who have progressed on treatment with either anastrozole or letrozole in any setting
Secondary
Objective Response at 6, 12, 20 and 28 Weeks
Objective Response at 6, 12, 20 and 28 weeks to assess the efficacy of AZD4547 in combination with anastrozole or letrozole. The Objective Response Rate (ORR) is defined as the proportion of overall complete response (CR) and overall partial response (PR) among all patients who receive at least one dose of study treatment. This outcome measure is based on local review.
Time frame: 6, 12, 20 and 28 weeks
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| AZD4547 | Objective Response at 6, 12, 20 and 28 Weeks | Objective response at week 6 | 0 Participants |
| AZD4547 | Objective Response at 6, 12, 20 and 28 Weeks | Objective response at week 12 | 2 Participants |
| AZD4547 | Objective Response at 6, 12, 20 and 28 Weeks | Objective response at week 20 | 3 Participants |
| AZD4547 | Objective Response at 6, 12, 20 and 28 Weeks | Objective response at week 28 | 3 Participants |
Secondary
Progression Free Survival
Progression Free Survival (PFS) was defined as the time from study enrolment to first evidence of progression. Progression is defined as overall progressive disease identified at follow-up or confirmed disease progression at the end of the trial or death.
Time frame: 42 months
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| AZD4547 | Progression Free Survival | 3.1 months |
Secondary
Proportion of Tumour Size Change at 6, 20 and 28 Weeks
Proportion of tumour size change at 6, 20 and 28 weeks to assess the efficacy of AZD4547 in combination with anastrozole or letrozole. This outcome measure is based on local review.
Time frame: 6, 20 and 28 weeks
Population: Out of 52 enrolled patients, 48 had analyzable data at 6th week, 41 at 20th week and 40 at 28th week. At specific time points, some patients may have withdrawn or already discontinued study medication.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| AZD4547 | Proportion of Tumour Size Change at 6, 20 and 28 Weeks | Proportion of tumour size change at week 6 | 0.04 Proportion of tumuour size change | Standard Deviation 0.29 |
| AZD4547 | Proportion of Tumour Size Change at 6, 20 and 28 Weeks | Proportion of tumour size change at week 20 | 0.09 Proportion of tumuour size change | Standard Deviation 0.36 |
| AZD4547 | Proportion of Tumour Size Change at 6, 20 and 28 Weeks | Proportion of tumour size change at week 28 | 0.10 Proportion of tumuour size change | Standard Deviation 0.36 |
Secondary
Tumour Response (RECIST Criteria) at 6, 12, 20 and 28 Weeks
Tumour response (RECIST criteria) at 6, 12, 20 and 28 weeks to assess the efficacy of AZD4547 in combination with anastrozole or letrozole. This outcome measure is based on local review.
Time frame: 6, 12, 20 and 28 weeks
| Arm | Measure | Group | Category | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|---|
| AZD4547 | Tumour Response (RECIST Criteria) at 6, 12, 20 and 28 Weeks | Overall response at week 20 | Complete response | 0 Participants |
| AZD4547 | Tumour Response (RECIST Criteria) at 6, 12, 20 and 28 Weeks | Overall response at week 20 | Partial response | 2 Participants |
| AZD4547 | Tumour Response (RECIST Criteria) at 6, 12, 20 and 28 Weeks | Overall response at week 20 | Stable disease | 13 Participants |
| AZD4547 | Tumour Response (RECIST Criteria) at 6, 12, 20 and 28 Weeks | Overall response at week 12 | Stable disease | 18 Participants |
| AZD4547 | Tumour Response (RECIST Criteria) at 6, 12, 20 and 28 Weeks | Overall response at week 6 | Complete response | 0 Participants |
| AZD4547 | Tumour Response (RECIST Criteria) at 6, 12, 20 and 28 Weeks | Overall response at week 6 | Partial response | 2 Participants |
| AZD4547 | Tumour Response (RECIST Criteria) at 6, 12, 20 and 28 Weeks | Overall response at week 6 | Stable disease | 31 Participants |
| AZD4547 | Tumour Response (RECIST Criteria) at 6, 12, 20 and 28 Weeks | Overall response at week 6 | Progressive disease | 16 Participants |
| AZD4547 | Tumour Response (RECIST Criteria) at 6, 12, 20 and 28 Weeks | Overall response at week 6 | Progressive disease before scan | 1 Participants |
| AZD4547 | Tumour Response (RECIST Criteria) at 6, 12, 20 and 28 Weeks | Overall response at week 6 | Withdrawn before scan | 2 Participants |
| AZD4547 | Tumour Response (RECIST Criteria) at 6, 12, 20 and 28 Weeks | Overall response at week 6 | Scan not done or not available | 0 Participants |
| AZD4547 | Tumour Response (RECIST Criteria) at 6, 12, 20 and 28 Weeks | Overall response at week 12 | Complete response | 0 Participants |
| AZD4547 | Tumour Response (RECIST Criteria) at 6, 12, 20 and 28 Weeks | Overall response at week 12 | Partial response | 1 Participants |
| AZD4547 | Tumour Response (RECIST Criteria) at 6, 12, 20 and 28 Weeks | Overall response at week 12 | Progressive disease | 8 Participants |
| AZD4547 | Tumour Response (RECIST Criteria) at 6, 12, 20 and 28 Weeks | Overall response at week 12 | Progressive disease before scan | 17 Participants |
| AZD4547 | Tumour Response (RECIST Criteria) at 6, 12, 20 and 28 Weeks | Overall response at week 12 | Withdrawn before scan | 6 Participants |
| AZD4547 | Tumour Response (RECIST Criteria) at 6, 12, 20 and 28 Weeks | Overall response at week 12 | Scan not done or not available | 2 Participants |
| AZD4547 | Tumour Response (RECIST Criteria) at 6, 12, 20 and 28 Weeks | Overall response at week 20 | Progressive disease | 3 Participants |
| AZD4547 | Tumour Response (RECIST Criteria) at 6, 12, 20 and 28 Weeks | Overall response at week 20 | Progressive disease before scan | 26 Participants |
| AZD4547 | Tumour Response (RECIST Criteria) at 6, 12, 20 and 28 Weeks | Overall response at week 20 | Withdrawn before scan | 8 Participants |
| AZD4547 | Tumour Response (RECIST Criteria) at 6, 12, 20 and 28 Weeks | Overall response at week 20 | Scan not done or not available | 0 Participants |
| AZD4547 | Tumour Response (RECIST Criteria) at 6, 12, 20 and 28 Weeks | Overall response at week 28 | Complete response | 0 Participants |
| AZD4547 | Tumour Response (RECIST Criteria) at 6, 12, 20 and 28 Weeks | Overall response at week 28 | Partial response | 2 Participants |
| AZD4547 | Tumour Response (RECIST Criteria) at 6, 12, 20 and 28 Weeks | Overall response at week 28 | Stable disease | 10 Participants |
| AZD4547 | Tumour Response (RECIST Criteria) at 6, 12, 20 and 28 Weeks | Overall response at week 28 | Progressive disease | 1 Participants |
| AZD4547 | Tumour Response (RECIST Criteria) at 6, 12, 20 and 28 Weeks | Overall response at week 28 | Progressive disease before scan | 30 Participants |
| AZD4547 | Tumour Response (RECIST Criteria) at 6, 12, 20 and 28 Weeks | Overall response at week 28 | Withdrawn before scan | 9 Participants |
| AZD4547 | Tumour Response (RECIST Criteria) at 6, 12, 20 and 28 Weeks | Overall response at week 28 | Scan not done or not available | 0 Participants |